<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32496361</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-7355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>8S</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases</Title>
          <ISOAbbreviation>J Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Auto-Inflammatory Syndromes Revealing Hematological Disorders and Anakinra Efficacy in 2 Cases.</ArticleTitle>
        <Pagination>
          <StartPage>S403</StartPage>
          <EndPage>S404</EndPage>
          <MedlinePgn>S403-S404</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/RHU.0000000000001425</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brevet</LastName>
            <ForeName>Pauline</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curie</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Princivil</LastName>
            <ForeName>Christelle</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zarnitsky</LastName>
            <ForeName>Charles</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alcaix</LastName>
            <ForeName>Didier</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Rheumatol</MedlineTA>
        <NlmUniqueID>9518034</NlmUniqueID>
        <ISSNLinking>1076-1608</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="Y">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053590" MajorTopicYN="Y">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32496361</ArticleId>
        <ArticleId IdType="doi">10.1097/RHU.0000000000001425</ArticleId>
        <ArticleId IdType="pii">00124743-202112003-00025</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018;77:1558–1565.</Citation>
        </Reference>
        <Reference>
          <Citation>Arranz L, Arriero MDM, Villatoro A. Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood Rev. 2017;31:306–317.</Citation>
        </Reference>
        <Reference>
          <Citation>Dinarello CA. Why not treat human cancer with interleukin-1 blockade?Cancer Metastasis Rev. 2010;29:317–329.</Citation>
        </Reference>
        <Reference>
          <Citation>Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337–2344.</Citation>
        </Reference>
        <Reference>
          <Citation>Jachiet V, Mekinian A, Carrat F, et al. Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leuk Lymphoma. 2018;59:1399–1405.</Citation>
        </Reference>
        <Reference>
          <Citation>Hofheinz K, Schett G, Manger B. Adult onset Still's disease associated with malignancy-cause or coincidence?Semin Arthritis Rheum. 2016;45:621–626.</Citation>
        </Reference>
        <Reference>
          <Citation>Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–2252.</Citation>
        </Reference>
        <Reference>
          <Citation>Grignano E, Jachiet V, Fenaux P, et al. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018;97:2015–2023.</Citation>
        </Reference>
        <Reference>
          <Citation>Ustwani OA, Ford LA, Sait SJ, et al. Myelodysplastic syndromes and autoimmune diseases—case series and review of literature. Leuk Res. 2013;37:894–899.</Citation>
        </Reference>
        <Reference>
          <Citation>Fraison JB, Mekinian A, Grignano E, et al. Efficacy of azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016;43:13–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Cavalli G, Foppoli M, Cabrini L, et al. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:13.</Citation>
        </Reference>
        <Reference>
          <Citation>Tomelleri A, Cavalli G, De Luca G, et al. Treating heart inflammation with interleukin-1 blockade in a case of Erdheim-Chester disease. Front Immunol. 2018;9:1233.</Citation>
        </Reference>
        <Reference>
          <Citation>Luft T, Jefford M, Luetjens P, et al. IL-1 beta enhances CD40 ligand–mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell–independent DC activation. J Immunol. 2002;168:713–722.</Citation>
        </Reference>
        <Reference>
          <Citation>Voronov E, Apte RN. Targeting the tumor microenvironment by intervention in interleukin-1 biology. Curr Pharm Des. 2017;23:4893–4905.</Citation>
        </Reference>
        <Reference>
          <Citation>Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}–induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84:114–122.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
